Hepatitis resulting from infection with viruses other than hepatitis A virus (HAV) and hepatitis B virus was previously referred to as non-A, non-B hepatitis (NANBH) (13, 15, 23) . The diagnosis of NANBH was one of exclusion: i.e., demonstrating the absence of serologic markers for acute infection with HAV or hepatitis B virus. At least two epidemiologically distinct forms of NANBH were recognized and further substantiated by transmission studies in primates (1, 5, 8, 24) . These different viruses were transmitted by either the parenteral or fecal-oral routes. The designation of NANBH therefore formerly represented a diverse collection of uncharacterized but etiologically distinct agents. The first characterized NANBH agent was that responsible for parenterally transmitted NANBH, or what is now called hepatitis C virus (10) . This was followed by the cloning of a portion of the fecal-orally transmitted agent, the hepatitis E virus (HEV) (19) . The latter form of virus-induced hepatitis has been referred to as enterically transmitted NANBH (ET-NANBH).
Epidemics of ET-NANBH have been recognized worldwide but occur principally in developing countries. They have been reported in southeast Asia, central Asia, Africa, Mexico, and Central America (6, 7, 16) . In these areas, contaminated water has been implicated as the principle vehicle of virus transmission. Although HEV and HAV are transmitted in a similar manner, there are major differences in the clinical, pathological, and epidemiological courses of these two viruses. In particular, the mortality rate for HEV infection is 1 to 2%, or approximately 10-fold greater than that seen for HAV. Infection with HEV is particularly fatal by clinical presentation and the lack of a serologic response to HAV and hepatitis B virus or by other predisposing conditions, exposures, or infections that can cause hepatitis.
An immune response to viruslike particles (VLPs) in acutephase stool samples has been observed by using immunoelectron microscopy (7, 8, 16) . However, most clinical specimens do not have sufficient VLPs in order for immunoelectron microscopy to be a useful tool for clinical or epidemiologic surveys.
The serial passage of HEV in cynomolgus macaques has been reported previously (2, 3, 5, 8) . In this primate model, the disease typically results in elevated liver enzymes and the detection of VLPs in both stool and bile. The development of a competent animal model for studies of human HEV has greatly assisted in the serologic characterization of HEV. It has been found that sera from geographically distinct outbreaks and experimentally infected cynomolgus monkeys will aggregate VLPs in human case stool specimens, thereby suggesting that one major virus is responsible for the majority of ET-NANBH observed worldwide (8) .
We demonstrate that cDNA clones isolated from a lambda gtll expression library are derived from the HEV genome and are specifically reactive with acute-and convalescentphase sera collected from individuals infected in the course of ET-NANBH epidemics. The serologic data presented here provide further evidence for HEV as the predominant etiologic agent of ET-NANBH. These results indicate the existence of type-common viral epitopes which appear to be HEV: IDENTIFICATION OF TYPE-COMMON EPITOPES   5791 shared by divergent geographic isolates from Asia and North America.
MATERIALS AND METHODS Human sera. Human serum samples were collected during ET-NANBH outbreaks in Pakistan, Mexico, Burma, Borneo, the USSR, and Somalia (7). Control sera were from individuals in the United States with no known history of exposure to HEV or travel to areas in which ET-NANBH is endemic. Acute-phase sera were collected between 1 and 12 days after the onset of symptoms. Convalescent-phase sera were collected from asymptomatic individuals between 30 and 90 days after the onset of jaundice. Any nonspecific reactivity in human sera against bacterium-derived proteins was removed by incubating appropriate serum dilutions with nitrocellulose filters prepared by using nonrecombinant lambda phage plated as described in the screening protocols below.
Cynomolgus macaque sera. Wild-caught cynomolgus macaques were quarantined for 6 to 8 weeks after importation (from the Philippines) and bled twice weekly for approximately 2 months to establish baseline liver enzyme profiles prior to infection (8) . In brief, cynomolgus monkeys were intravenously infected with a 10% filtered stool suspension prepared from human stool samples collected during HEV outbreaks in Burma, Pakistan, and Mexico (7, 8) . Serial passage of HEV in animals was by intravenous inoculation with a filtered 10% suspension of early-phase or pre-acutephase cynomolgus macaque stool filtrates. Cynomolgus monkey stools were analyzed by immunoelectron microscopy for the presence of disease-associated 27-to 34-nm VLPs. Acute-phase sera were collected within a 2-week period during the peak of alanine aminotransferase activity. Convalescent-phase sera were collected between 30 and 60 days after the return of alanine aminotransferase activity to preinoculation levels. Any possible seroreactivity to Escherichia coli-associated antigens was removed as described above.
Library construction. A human stool sample collected during an ET-NANBH outbreak in Mexico (Mex#14) (7) was used for cDNA library construction. A 10% fecal suspension was clarified by centrifugation and extracted for viral RNA by phenol-chloroform extraction. After ethanol precipitation of RNA, cDNA was synthesized by random priming of the first strand by using a cDNA synthesis kit (Boehringer Mannheim). AB linker-primer oligonucleotides were ligated to the blunt-ended cDNA. The design of the AB linker-primer permits sequence-independent single-primer amplification of the heterogeneous cDNA population by repetitive rounds of annealing, extension, and denaturing in the presence of the A strand of the AB double-stranded oligonucleotide (18) . After cleavage at the AB linker-primer EcoRI restriction site and purification of the cDNA from oligonucleotide fragments, cDNA libraries were constructed in the phage expression vector lambda gtll (27) .
Screening for HEV recombinant proteins. Recombinant cDNA libraries were screened for HEV specific antigenproducing clones by plating on E. coli KM392 (14) at 10,000 phage per 150-mm-diameter plate (27) . After (27) . The Coomassie blue stain of the protein gel; the other panels are Western blots of identically prepared gels that were tested with various human sera (normal and F387-C) and cynomolgus macaque sera (as noted above each panel).
TCTCGAGTTTTTTTTTTTTTTTTTTTT-3' (3' primer). HEV(B) cynomolgus monkey liver cDNA clones containing the regions homologous to the identified HEV(M) epitopes were mixed with the appropriate primers and then subjected to 30 cycles of PCR amplification using Taq polymerase (20) . These primers were modified to contain EcoRI restriction sites to facilitate in-phase subcloning. The PCR-amplified material was digested with proteinase K and cleaved with EcoRI, and the resulting DNA fragments were gel purified before ligation into lambda gtll. Insert-containing phage were identified by hybridization, and the production of HEV(B)-specific antigen was verified by immunoscreening as described above.
RESULTS
Isolation and characterization of HEV type-common epitopes. A portion of the HEV genome was first identified by differential hybridization of a cDNA library made from the bile of a Burma strain-infected cynomolgus macaque (19) . The recognition of consensus sequences for the RNAdirected RNA polymerase had established the clone as derived from the nonstructural portion of the viral genome.
Immunoscreening is an alternative approach to identification of clones from regions of the genome likely to encode structural genes. A human stool-derived lambda gtll library was therefore constructed from a stool sample collected during the Telixtac, Mexico, ET-NANBH outbreak (7) .
Previous attempts at cloning HEV from stool samples had met with little success because of the low numbers of viral particles excreted in feces. In order to ensure that the cDNA library was representative of all extracted nucleic acid species present in feces, it would be necessary to expand the starting cDNA to facilitate the recovery of an HEV-specific clone. This was accomplished by the application of sequence-independent single-primer amplification to permit the nonselective enzymatic amplification of all cDNAs present in the initial starting material (18, 19) .
The resulting high-titer library was screened for HEVspecific antigen-producing clones by using a different convalescent human serum sample (F387-C) collected during the same Telixtac, Mexico, outbreak. Two positive immunoreactive plaques were isolated out of a total of 70,000 phage screened. These lambda gtll clones, 406.4-2(M) and 406.3-2(M), were plaque purified and lysogenized in E. coli BNN103, and ,-galactosidase recombinant fusion proteins were induced (see Materials and Methods). The molecular weights of the expressed 1-galactosidase fusion proteins for 406.4-2(M) (-120,000) and 406.3-2(M) (-123,000) indicated that they both had relatively small inserts compared with the nonrecombinant fusion protein ( Fig. 1; see below) . Crude, unpurified lysates from these lysogens were resolved by polyacrylamide gel electrophoresis, blotted onto nitrocellulose, and subsequently tested with human and cynomolgus monkey sera to confirm that the observed plaque reactivity was specific for the induced fusion protein (Fig. 1) . The (Fig. 1) . The weak reactivity of the 406.3-2(M) protein in the denatured Western blot format (Fig. 1) suggested that the native protein conformation associated with the lambda plaque screening assay might provide better sensitivity in detecting specific anti-HEV antibody. The reactivity of the 406.4-2(M) and 406.3-2(M) recombinant clones was therefore tested with 12 human and 12 cynomolgus monkey serum samples in a plaque assay format. As shown in Table 1 , both recombinant clones immunoreacted specifically with acuteand convalescent-phase human sera collected during outbreaks in different geographic locations (7) . The 406.4-2(M) clone immunoreacted with 9 of 11 and the 406.3-2(M) clone immunoreacted with 8 of 11 serum samples derived from HEV-infected individuals. Although the absolute number of serum samples tested was small, it is important to note that both 406.3-2(M) and 406.4-2(M) reacted with sera from five of five different epidemics. This screening strongly suggested that the identified epitopes were broadly reactive and represented HEV type-common epitopes.
Both Mexico strain clones were also recognized by antibodies from acute-and convalescent-phase sera obtained from experimentally infected cynomolgus macaques ( Table  2 ). As noted above, the 406.4-2(M) clone was recognized by sera from HEV-infected individuals from all five geographic locations; however, only sera from the HEV(M)-infected cynomolgus monkeys were found to be reactive. This contrasted with the cross-strain reactivity of the 406.3-2(M) clone to acute-and convalescent-phase sera from both Burma and Mexico strain-infected cynomolgus macaques. b Acute-phase sera were collected during peak alanine aminotransferase activities. Convalescent-phase sera were collected after the return of alanine aminotransferase activity to preinoculation levels. Control sera were preimmune sera from the corresponding HEV-infected cynomolgus monkey. (Fig. 1) Immunoreactivity for these Burma strain-derived clones was found to be identical to that for the original Mexico strain clones when they were tested with selected samples from the panel of sera from HEV-infected individuals (Table  1) . These Burma strain clones were also recognized by antisera from cynomolgus macaques infected with the HEV(B) agent ( Fig. 2A . Comparison of these sequences with those in the GenBank data base (version 64) indicated that these viral sequences were novel. As noted above, HEV(M) sequences were also compared with the full-length sequence of HEV(B) (25) to isolate the equivalent regions. The nucleotide sequence comparison indicated 78.5% similarity for the 406.4-2 region and 79.8% similarity for the 406.3-2 epitope region. The amino acid similarity for 406.4-2(M) was only 73.5% (over 34 amino acids). This contrasted with the 90.5% identity of clone 406.3-2(M) with the equivalent HEV(B) sequence in a 42-amino-acid overlap (Fig. 2B) . This sequence divergence in the respective epitope regions could account for the observed variation noted in the antigen profiling with cynomolgus macaque sera (see above).
An independent cDNA isolation experiment indicated that (25) . It was surprising, however, to discover that the 406.4-2 epitope region mapped to ORF3. ORF3 overlaps ORFi at its 5' end (by 1 bp) and ORF2 at its 3' end, encompassing only 123 amino acids from the first methionine residue to its termination codon. It is apparent that the full-length sequence of the 406.4-2(M) cDNA insert does not encode protein; the first termination codon for ORF3 can be seen at nucleotide residue 120, with other termination codons (Z) present throughout the sequence (Fig. 2A) . The epitope rescue of a comparable Burma strain sequence was directed to the initial 33 amino acids found in frame with ,-galactosidase. The utilization of ORF3 would not have been predicted were it not for its random selection by antibody screening.
HEV cDNA clones identify subgenomic RNAs. It was previously determined that the full-length genome of HEV was a polyadenylated, positive-sense RNA of -7.5 kb (17, 19) . In order to definitively confirm the viral origin of the cDNA epitope clones, they were used as hybridization probes against Northern blots of total and polyadenylated fractions of RNAs extracted from HEV(M)-and HEV(B)-infected as well as uninfected cynomolgus macaque livers. These same infected specimens were previously shown to be positive for HEV-specific transcripts (19) . As shown in Fig. 3 (lane M) , polyadenylated transcripts of -7.5, -3.7, and -2.0 kb were detected only in liver RNAs from HEV(M)-infected cynomolgus monkeys by using clone 406.4-2(M) as a probe. Identical hybridization results were obtained by using 406.3-2(M) as a probe (data not shown). The detection of subgenomic transcripts of -3.7 and -2.0 kb was surprising in that only the full-length genomic transcript of 7.5 kb was previously detected in these same samples (19) . However, the probe utilized was located in what is considered the nonstructural region of the genome and 5' to that encoding the epitope clones (19) . Under the stringent conditions utilized in this hybridization analysis, the HEV(M)-derived probe [78.5% homologous to the HEV(B) epitope] did not detect comparable transcripts in the Burma strain-infected animal (Fig. 3, lane B) . Subgenomic transcripts were confirmed in HEV(B)-infected liver by hybridization using a cDNA clone that overlapped with the sequence represented by the 406.4-2(M) clone (25 (19) . Subsequent molecular characterization led to the recognition that the clone was derived from the major causative agent of ET-NANBH worldwide (7, 16) . The molecular epidemiology was in agreement with the previous studies on virus particle aggregation by heterologous sera that suggested that a single predominant agent was responsible for ET-NANBH (7, 8 efforts (19) . The isolated cDNA clones are certainly derived from immunogenic viral proteins and may represent epitopes from the structural region of the virus. The two cDNA clones, 406.4-2(M) and 406.3-2(M), were identified directly from human stool by using human sera and therefore represent not only the initial isolation of HEV(M) strain clones but also the expression of recombinant epitopes recognized in the naturally infected host. The epitopes specifically reacted with human acute-and convalescent-phase sera and were also recognized by sera from experimentally infected cynomolgus macaques. Assays for the determination of HEV infection are presently unavailable, but their feasibility has been demonstrated here. Our interest has been in the molecular characterization of HEV, recognizing that the characterization of virus-encoded protein products may be useful in the diagnosis and treatment of what is believed to be the cause of the majority of epidemic and sporadic viral hepatitis cases seen in developing countries.
Molecular analysis of the recently cloned viral genome for HEV(B) indicates that HEV is different from other RNA viruses known to cause hepatitis. The ORF analysis of HEV(B) (25) suggests a genomic organization different from that of the picornavirus HAV (12) or the flavivirus-or pestiviruslike virus, hepatitis C virus (10) . The. blind immunoscreening approach described in this paper succeeded in isolating immunodominant epitopes of HEV and has aided in the elucidation of the expression strategy employed by the virus. The utilization of ORF3 was not predicted, but its expression in the infected liver was confirmed by the numerous sera that reacted with its product (406.4-2). The exact means by which this small ORF3 reading frame is expressed is not known but presumably involves the subgenomic transcripts that are coterminal with the 3' end of the virus. The Northern analysis of RNA isolated from HEV(M) indicated that there were two subgenomic, polyadenylated viral mRNAs of 2.0 and 3.7 kb. It is possible that the structural gene(s) of the virus is expressed by these subgenomic transcripts, as seen with the Alphavirus genus (e.g., Sindbis virus [22] ). Although the genomic organization of HEV shows some similarity to alphaviruses, sequences which have been found to be highly conserved between alphaviruses have not been found in HEV (13a). Final classification of HEV will depend on the biochemical characterization of the protein products encoded by this virus and the genomic organization and expression strategy of its structural and nonstructural proteins.
The understanding of the complete immune response to HEV infection will require delineation of the humoral and cellular immune responses to this agent. We have preliminary indications that the antibody response to these particular epitopes may have utility in the diagnosis of ET-NANBH by confirming past and present exposure to HEV. Further studies will be required in order to determine whether these same epitopes elicit protective immunity or are involved in the cellular immune response to virus infection.
